Duane Reade revenues
This article was originally published in The Tan Sheet
Executive Summary
Same-store sales rise 3% for drugstore chain in second quarter ended Sept. 30. Overall sales of $338.6 mil. in period fall $11.4 mil. below company's previously issued expectations. Duane Reade 1cites Aug. 14 blackout for $3.3 mil. of sales loss, as well as Claritin and Prilosec Rx-to-OTC switches for slowing pharmacy growth. Firm lowers third quarter earnings expectations from 15¢ to 20¢ cents to 8¢ to 9¢ cents per share. "We are experiencing the impact of lower growth in our prescription sales resulting from pharmacy to over-the-counter conversions, reduced demand in certain areas, as well as an increase in the number of uninsured," CEO Anthony Cuti says Oct. 6...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.